RLMD — Relmada Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$4.54
+$0.08 (+1.79%)
Relmada Therapeutics Inc (RLMD) is a biotechnology company listed on NASDAQ. It is led by Sergio Traversa M.B.A., Pharm.D., based in 2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134, with about 17 employees. Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Net income was -$10.1M. RLMD currently screens at market cap $692.3M.
Use this RLMD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RLMD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RLMD SEC filings page. Lician reads the product cache first so this HTML stays unique to Relmada Therapeutics Inc even when a live quote feed is slow.
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Key Statistics
Market Cap
$692.28M
Volume
249,903
Previous Close
$4.59
Day Range
$4.46 – $4.58
P/B Ratio
3.16
EPS
-$2.65
Revenue
$0.00
Net Income
-$79.98M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
17
RLMD Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$79.98M | -$98.79M | -$157.04M |
| EPS (Diluted) | -$2.65 | -$3.28 | -$5.30 |
Total Assets
$45.82M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.86M
Operating Cash Flow
-$51.76M
Free Cash Flow
$0.00
Relmada Therapeutics Inc Company Information
- CEO & Director
- Sergio Traversa M.B.A., Pharm.D.
- Headquarters
- 2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134
- Website
- www.relmada.com
- Phone
- 786 629 1376
- IPO / Founded
- 2014-10-09
- Sector
- Healthcare
- Industry
- Biotechnology